Inflammation-Based INFLAME-MI Score Enhances Early Risk Assessment Post-MI

Overview

The INFLAME-MI score, incorporating inflammatory biomarkers and routine clinical parameters, demonstrates good calibration and clinical utility for predicting in-hospital mortality after acute myocardial infarction. While not superior in discrimination to the GRACE score, INFLAME-MI better aligns predicted and observed mortality, especially in low-to-intermediate risk patients.

Background

Acute coronary syndromes (ACS) are heterogeneous, necessitating accurate early risk stratification to guide management and secondary prevention. Traditional tools like the GRACE score have evolved but have limitations in guiding invasive strategies. Inflammation plays a causal role in atherogenesis and post-ACS outcomes, with biomarkers such as neutrophil count and C-reactive protein linked to prognosis. Integrating inflammatory markers into risk models may refine prognostication after myocardial infarction.

Data Highlights

Key Findings

• INFLAME-MI score integrates nine routinely available parameters, including inflammatory biomarkers, to predict in-hospital mortality after myocardial infarction.
• The score shows good discriminatory ability (AUC 0.88–0.92) but is not statistically superior to the GRACE score in discrimination.
• INFLAME-MI demonstrates superior calibration, closely matching predicted and observed mortality, unlike GRACE which overestimates risk.
• Net reclassification improvement and decision curve analyses reveal greater clinical net benefit of INFLAME-MI in low-to-intermediate risk ACS patients.
• The model was derived from a single-center cohort and externally validated in a small population, highlighting the need for larger prospective studies.
• Improved risk prediction does not automatically translate into changes in clinical management; further research is needed to assess impact on decision-making.

Clinical Implications

The INFLAME-MI score offers a simplified, inflammation-focused tool that may complement existing risk models like GRACE in early ACS management. Its improved calibration and clinical utility in low-to-intermediate risk patients could aid clinicians in refining prognosis and tailoring interventions. However, due to limited validation, it should be used cautiously until further large-scale studies confirm its utility and impact on outcomes.

Conclusion

INFLAME-MI represents a biologically coherent and innovative approach incorporating inflammation into early risk stratification after myocardial infarction. While promising, further validation is required before routine clinical adoption.

References

1. Sadler et al. 2024 -- INFLAMMation in Acute Myocardial diseases risk Estimation for Myocardial Infarction (INFLAME-MI) score
2. GRACE Study Group -- Development and validation of GRACE risk scores
3. Altman and Bland 1995 -- Absence of evidence is not evidence of absence